Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLMSCs in SPMS
NCT06360861Phase 1Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2019
- Primary completion
- Mar 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of placenta-derived mesenchymal stem cells in secondary-progressive multiple sclerosis (SPMS), sponsored by Tehran University of Medical Sciences. Primary endpoint: Treatment-Emergent Adverse Events at 6 months. Started Jul 2019; status: completed.
02
Drugs
placenta-derived mesenchymal stem cells
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT06360861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06360861.